rag2riches
Posted - 1 day ago
$ONCT may 14th 10am we could potentially see a abstract at EHA for onct-808
rag2riches
Posted - 1 day ago
$ONCT saw a trial on progress poster for onct 534. No clinical data at asco for 534 or 808
rag2riches
Posted - 3 days ago
$ONCT Wednesday 10am press release for onct 808 and 534 abstract at asco 2024
Drew613
Posted - 1 week ago
$ONCT tempted to buy more but can’t get the price I want.
rag2riches
Posted - 1 week ago
$ONCT oppenheimrr analyst report must have triggered this random press release from oncternal. In the report the doctor highlights adverse events as I pointed out in my previous post so onct must have had this PR sent out quickly and leafing with "safety". What this PR confirms is that they have no hit therapeutic doses. When I read the PR I first though it would be for onct-808 which would make sense since we still don't know if they treated new patients at lower doses.
Next Wednesday we will know if onct 808 or onct 534 data will be presented at asco. Expect a press release by 10am that day
Stock_Titan
Posted - 1 week ago
$ONCT Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
https://www.stocktitan.net/news/ONCT/oncternal-announces-first-patient-dosed-in-fourth-cohort-of-phase-1-6x14g7nqbgxt.html
rag2riches
Posted - 1 week ago
$ONCT oppenheimer analyst report posted today. They interviewed a physician in which I suspect is involved or has visibility into the onct -534 trial. His practice location is on the trial. He may even be an investigator three.
They asked him when to expect data and he said 2q24 (aligned to company guidance) but more importantly he called out some data points
PSA reductions, correlation of radiographic responses, and other things. He also mentioned he expects adverse events such as weight gain, muscle loss, and sexual issues. Also potential for QT prolongation. Looks like it may be a dirty drug. This guy also expects this drug to cover prostate broadly based on MoA.
wtzou
Posted - 1 week ago
$ONCT volume is 1367 shares at 1pm.
Drew613
Posted - 1 week ago
$ONCT is officially 15% of my entire portfolio. Many years here and expect great things. Although I am a bit frustrated with the pace here.🤞
rag2riches
Posted - 2 weeks ago
$ONCT novartis just licensed a preclinical AR-V7 prostate asset for 150 million and up to 10 BILLION in milestones. Guess what, ONCT-534 also has this mechanism of action. Onct-534 is already in the clinic with data expect this year. If novartis is interested and licensing a PRECLINICAL asset then oncternal must be having discussions with big pharma as we speak
insiderbuyingselling
Posted - 2 weeks ago
$ONCT new insider buying: 3086 shares. http://insiderbuyingselling.com/?t=ONCT
_StockTrader
Posted - 2 weeks ago
Real-Time Stock Data $ONCT
Price: N/A
Volume: 9558
Market Cap: 25697370
PE Ratio: -0.8470829
Powered by: AITX
pablin
Posted - 2 weeks ago
$ONCT
Drew613
Posted - 2 weeks ago
$ONCT C’mon Jimmy give us something for crying out loud!
We’ve been sitting on dead money and big losses for years now.
Locke1
Posted - 3 weeks ago
$ONCT these 10% swings up and down and up and down…..wtf?
rag2riches
Posted - 3 weeks ago
$ONCT 900 Million biobuck by Ipsen for Sutro's ROR1 ADC
https://www.fiercebiotech.com/biotech/ipsen-joins-adc-race-900m-biobuck-deal-sutro-chase-same-target-merck-boehringer
It's ashame the mAb zilovertamab is not getting as much attention as the ADC. Oncternal needs to push the gas on ONCT-808 before these ADCs surpass it in clinical development. ROR1 CAR T I believe would be more efficacious than any of the ADCs. They really need to partner this asset with a cell therapy company such as Kite, BMS, JnJ. AZ is acquiring alot of car t programs and regeneon building up their cell therapy portfolio too.
ONCT-808 is the first ror1 cart to have lymphoma data (that I'm aware of) and it should have drawn alot of attention from these cell therapy developers. An ASCO/EHA poster I anticipate to be announced soon.
insiderbuyingselling
Posted - 3 weeks ago
$ONCT new insider buying: 6914 shares. http://insiderbuyingselling.com/?t=ONCT
rag2riches
Posted - 3 weeks ago
$ONCT corporate presentation updated. Only key difference I noticed was they show the car t persistence for the 3 patients which looks very good. They removed the axi-cel benchmark, not sure why, but I'm assuming onct 808 expansion doesn't look better than the axi-cel benchmark. If someone has an older corporate presentation you can see they benchmarked 1 patient to axicel. Now you don't see that. Which is odd.
RollingDollar
Posted - 3 weeks ago
$ONCT
rag2riches
Posted - 3 weeks ago
$ONCT onct 808 trial updated yesterday with 2 additional recurring sites at Massachusetts. New protocol amendment must be active now (at least at these two new sites).
Expect first patients treated in a month and then getting thru the dose escalation in about 3-6 months. Updated data expected in about the same time the study started recruitment to Dec 2023 when we saw initial data (too lazy to check how long this took but I'll say 1 year)
wtzou
Posted - 03/27/24
$ONCT listening to the Oppenheimer Fireside chat on ONCT-534. Dr. James Breitmeyer,: "You know, this is a this is an exciting field, this drug. If this does what we. what we hope it's going to do would be a dramatic value driver for the company. And we think that there's there's there's potential midyear here for both investors and potential pharmaceutical partners to have enough information available to to stimulate interest in the company." Source: https://investor.oncternal.com/news-and-events/events-presentations
Drew613
Posted - 03/26/24
$ONCT A true winner lol!
Wonder if Jimmy would invest in his own company. He needs to take notes from Viking’s CEO.
ViractaTrader77
Posted - 1 month ago
$MBRX $50 million market cap equates to $25 per share. this will be one of those screamers that has good data and everyone buys it up. https://player.vimeo.com/video/915686201?h=fb9d821f85 $ONCT $ADCT
bbonct
Posted - 1 month ago
$ONCT Anyone listen to the fireside chat? I was expecting another question and answer between Jim and Hartaj. That was far from the case. They had a well recognized guest speaker on prostate cancer, Dr Yu from UW, Division of Hematology and Oncology. I would love to hear your thoughts/interpretation. I sensed some euphoria regarding the treatment. With that said, I really want this to work, so I am sure my biases are seeking/creating positive signals. Nonetheless, there were so many great data points in this discussion that it keeps me bullish and even more excited. It was worth the hour. It’s solely on ONCT-534.
Drew613
Posted - 1 month ago
$ONCT more action in watching grass grow than this pos.
Stock_Titan
Posted - 1 month ago
$ONCT Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
https://www.stocktitan.net/news/ONCT/oncternal-participating-in-virtual-fireside-chat-with-key-opinion-xa75usxpi0oo.html
Drew613
Posted - 1 month ago
$ONCT honestly, all bios did bad today. The only thing is on good days, onct still does bad. Jimmy needs to build a little investor confidence. He hasn’t done one thing right imo. Shit’s getting old!
Drew613
Posted - 1 month ago
$ONCT less than .40 cents pre- reverse split. Result of amateur, untrustworthy management. Still keeping my fingers crossed!🤞
pablin
Posted - 1 month ago
$ONCT Its going to be a very long until july!!!
